R.CunninghamA.ChakrabarttyS.PandeV.ChakrabarttyA
These drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Other potential risks include: Acute pancreatitis Gallbladder disease (cholelithiasis, cholecystitis) Acute kidney injury Hypersensitivity reactions Patients should be monitored for persistent abdominal pain, changes in renal function, and other signs that may require discontinuation or additional workup
Lack of a Single Molecule May Indicate Severe and Treatment Resistant Depression
Berberine, the most researched natural GLP-1 supporter, produces approximately 4.5 pounds of weight loss in meta-analyses
Kishimoto T, Akira S, Narazaki M, Taga T
"Drug Approval Package: Januvia (Sitagliptin Phosphate) NDA #021995"